2025 Oct 27, 05:39
Applied Molecular Transport Inc. has successfully completed its strategic combination with Cyclo Therapeutics Inc. The merger, which was initially announced on September 21, 2023, involved the union of several entities, including Cameo Merger Sub Inc., as well as AMTI and Cyclo themselves. Under the terms of the Merger Agreement, Merger Sub merged with and into AMTI, resulting in AMTI becoming a wholly-owned subsidiary of Cyclo. The Effective Time of the Merger took place on December 27, 2023
It is important to note that the above description is not comprehensive and should be read in conjunction with the Merger Agreement. For a complete understanding of the merger, reference should be made to the Merger Agreement itself. This document can be found as Exhibit 2.1 in the Current Report on Form 8-K, filed by AMTI on September 21, 2023. Incorporated herein by reference, the Merger Agreement provides crucial details about the merger and its implications. It is a significant milestone in the growth and development of both Applied Molecular Transport Inc
and Cyclo Therapeutics Inc. The completion of this strategic combination brings together the strengths and expertise of both entities, resulting in new and exciting possibilities for future advancements in the field. The successful merger is a testament to the dedication and hard work of all parties involved, who diligently executed the plan outlined in the Merger Agreement. Through this collaboration, Applied Molecular Transport Inc. and Cyclo Therapeutics Inc
strive to achieve greater success and to make a positive impact on the industries they serve. From this point forward, AMTI will operate as a wholly-owned subsidiary of Cyclo, contributing its specialized knowledge and resources to further enhance the capabilities of the combined entity. This joined force is expected to accelerate innovation and drive growth, benefiting not only the two companies but also their shareholders, employees, and customers worldwide. Overall, the completion of the strategic combination marks a significant milestone in the progression of Applied Molecular Transport Inc. and Cyclo Therapeutics Inc. It sets the stage for a new chapter of collaboration and breakthroughs, as these entities combine their respective strengths to push the boundaries of science and improve the lives of people globally. In conclusion, this merger signifies an exciting venture for both Applied Molecular Transport Inc
and Cyclo Therapeutics Inc., aligning their ambitions and resources to pave the way for future success. With AMTI now operating as a wholly-owned subsidiary of Cyclo, the two entities are poised to achieve remarkable achievements and advancements in the years to come.